All GLP-1 Journey Guides
115 hand-edited guides organized by topic, category, and medication. New guides go live every day.
eventMonth markers (Month 3 - 12) · 8 guides
Three-month checkpoints from month three through year one.
Month 12 on Semaglutide: One Year In
One year on semaglutide. STEP 1 reports ~14.9% mean weight loss at 68 weeks, close to plateau. Time to review labs, dose, and the long-term plan.
Read guidearrow_forwardMonth 12 on Tirzepatide: One Year of Treatment Reviewed
One year on tirzepatide. SURMOUNT-1 reports up to ~20.9% mean weight loss at 72 weeks on 15mg. Review labs, dose, lean mass, and the long-term plan.
Read guidearrow_forwardMonth 3 on Semaglutide: What 12 Weeks of Treatment Looks Like
Month 3 on semaglutide is the standard checkpoint. STEP trial data shows ~6% cumulative loss, the 1.0mg dose is settling, and the next titration is on deck.
Read guidearrow_forwardMonth 3 on Tirzepatide: The First Real Milestone
Month 3 on tirzepatide is the standard checkpoint. SURMOUNT-1 shows ~10% cumulative loss by 12 weeks on the higher dose. Time to review and plan.
Read guidearrow_forwardMonth 6 on Semaglutide: The Halfway Mark of a Year
Month 6 on semaglutide marks the halfway point. STEP 1 shows ~10% cumulative loss, the dose is approaching maintenance, and the trajectory is set.
Read guidearrow_forwardMonth 6 on Tirzepatide: Halfway Through the First Year
Month 6 on tirzepatide marks halfway. SURMOUNT-1 shows ~15% cumulative loss on the higher dose. Dose at 10mg, side effects routine, plateaus possible.
Read guidearrow_forwardMonth 9 on Semaglutide: Approaching Maintenance
Month 9 on semaglutide is where the curve begins to flatten. STEP 1 data shows ~13% cumulative loss, and the conversation shifts toward maintenance.
Read guidearrow_forwardMonth 9 on Tirzepatide: Where the Curve Levels Out
Month 9 on tirzepatide is where the steep loss curve begins to flatten. SURMOUNT-1 shows ~18% cumulative loss on the higher dose at this stage.
Read guidearrow_forward